|
Amicus Therapeutics develops drugs that treat rare genetic diseases known as lysosomal storage disorders. The company's enzyme replacement therapies are designed to target defective proteins and restore their functions. Its lead drug candidate, Amigal, is aimed at aiding patients with Fabry disease, whose symptoms include skin rashes, impaired sweating, and gastrointestinal, heart, and kidney problems that vary in severity. Amicus is also developing drugs to treat Gaucher disease, a disorder that can cause anemia and skeletal lesions, and Pompe disease, which causes muscle weakness and impairs breathing, mobility, and heart function.
|
| | | Contact Information | |
Address: |
6 Cedar Brook Dr.
Cranbury, NJ 08512
| | Phone: | 609-662-2000 | | Fax: | 609-662-2001 |
|
| Financial
Highlights | | Fiscal Year End: | December | | Revenue (2008): | 15.00 M | | Revenue Growth (1 yr): | 739.00% | | Employees (2008): | 115 | | Employee Growth (1 yr): | 0.00% |
|
|
Key People
| | • |
Chairman:
Donald J. Hayden Jr.
| | • |
President, CEO, and Director:
John F. Crowley
| | • |
COO:
Matthew R. Patterson
|
|
|
